Section
This review synthesizes evidence from the phase 3 GLISTEN trial and preceding studies on linerixibat, an ileal bile acid transporter inhibitor, demonstrating its efficacy and safety in reducing cholestatic pruritus in primary biliary cholan
A UK–Ireland partnership ranked the top research uncertainties for oesophagogastric cancers; priorities emphasize personalising multimodal treatment, nutrition and quality of life, and stronger patient-centred trial design to accelerate mea
An evidence-based synthesis of the 2025 Taipei Global Consensus II: 28 statements guiding H. pylori screening, eradication, surveillance and stewardship to reduce gastric cancer at individual and population levels.
A multicentre randomized trial found EUS-guided gastroenterostomy (EUS-GE) superior to surgical gastrojejunostomy (SGJ) for malignant gastric outlet obstruction—improving oral intake, shortening hospital stay, enhancing quality of life and
A randomized trial (ENDURO) found endoscopic ultrasound‑guided gastroenterostomy (EUS‑GE) enabled earlier resumption of solid food and was non‑inferior to surgical gastrojejunostomy for recurrent obstruction, supporting EUS‑GE as preferred
A multicentre randomized trial (NCT05548114) found endoscopic ultrasound‑guided gastroenterostomy (EUS‑GE) superior to surgical gastrojejunostomy (SGJ) for malignant gastric outlet obstruction, with faster return to solid diet, shorter hosp
Large clinical and functional study shows CTNNA1-truncating variants cause loss of αE-catenin via nonsense-mediated decay, confer substantially elevated risks of diffuse gastric cancer and lobular breast cancer versus general population but
A multi-cohort human study with mouse and Drosophila validation implicates gut microbes and the tryptophan metabolite 3‑hydroxyanthranilic acid in modulating attention in obesity, suggesting microbiota-directed interventions could improve c
A multicentre French ESD registry found that, after adjusting for size and morphology, large non‑pedunculated rectal polyps do not have higher rates of submucosal invasive cancer than equivalent colonic lesions; technical outcomes of ESD we
A pooled analysis of three population cohorts shows lean MASLD carries higher risks of liver-related events and all-cause and liver-related mortality despite lower cardiovascular event risk compared with non-lean MASLD.
Single‑cell and spatial profiling identify a PDE5A+ CAF subset that remodels stroma, activates PI3K/AKT/mTOR–CXCL12 signaling, and recruits exhausted LAG3+ CD8 T cells, promoting immune exclusion in gastric cancer. Vardenafil plus LAG3 bloc
A first large GWAS in 4,602 idiopathic achalasia patients implicates class II HLA variation, PTPN22, TNFSF loci and a memory CD8+ T-cell subtype in disease pathogenesis, supporting an immune-mediated aetiology and offering routes for mechan
A large Asian cohort study shows serum HBsAg <100 IU/mL reliably identifies inactive chronic hepatitis B patients whose annual HCC risk is <0.2%, potentially allowing de‑escalation of surveillance and informing partial HBV cure defini
In the phase 2 REEF‑IT trial, pegylated interferon‑α2a added to siRNA JNJ‑73763989 produced large HBsAg reductions and transient seroclearance in some untreated HBeAg‑positive patients, but no participant reached the prespecified sustained
A multinational cohort study of 1,986 patients with indeterminate chronic hepatitis B (CHB) shows large differences in long‑term hepatocellular carcinoma (HCC) risk by baseline indeterminate subtype and by phase transition, identifying subg
Pooled analysis of the ENHANCE and RESPONSE phase 3 trials shows seladelpar 10 mg reduces pruritus and sleep disturbance in patients with primary biliary cholangitis (PBC) and moderate-to-severe baseline itch versus placebo over 6 months, w
A multicentre retrospective cohort found that pretransplant immune-related adverse events (irAEs) markedly increase the risk of early liver allograft rejection after liver transplantation for hepatocellular carcinoma (HCC). IrAEs, short ICI
Nonceliac gluten/wheat sensitivity affects about 1 in 10 people worldwide, with strong links to female sex, psychological distress, and irritable bowel syndrome. This article explores its prevalence, symptoms, challenges in diagnosis, and i
The FDA has approved linaclotide (Linzess) for treating irritable bowel syndrome with constipation (IBS-C) in children 7 and older, marking the first official treatment option for pediatric IBS-C.
A multinational retrospective cohort found adjunctive plasma exchange was associated with higher 28‑day transplant-free survival in amatoxin-related ALF patients with grade ≥2 hepatic encephalopathy.
